Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Taamma, A."'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Kidney International 2 January 2007 71(2):126-133
Autor:
Vassal, S., Taamma, R., Marty, N., Sardet, A., d’Athis, P., Brémont, F., Dalphin, M.L., Plésiat, P., Rault, G., Thubert, J., Dominique, S., Lemeland, J.F., Derelle, J., Blech, M.F., Roussey, M., Perrin, M., Sautegeau, A.
Publikováno v:
In AJIC: American Journal of Infection Control October 2000 28(5):347-351
Autor:
Hasbini, A., Mahjoubi, R., Fandi, A., Chouaki, N., Taamma, A., Lianes, P., Cortès-Funes, H., Alonso, S., Armand, J.P., Cvitkovic, E., Raymond, E. *
Publikováno v:
In Annals of Oncology April 1999 10(4):421-425
Publikováno v:
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 31:450-458
Background It is well known that the efficiency of peritoneal dialysis (PD) varies with the duration of the dwell and with the prescribed fill volume. Automated PD (APD) is classically given as a series of recurrent exchanges, each having the same dw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2580ba366f74045d811a011328556f96
https://doi.org/10.3747/pdi.2010.00146
https://doi.org/10.3747/pdi.2010.00146
Publikováno v:
Kidney International. 71:126-133
Advanced glycation end-products (AGEs) inhibit ischemia-induced angiogenesis but are potential triggers of neoangiogenesis that occurs in peritoneal dialysis (PD) patients. We investigated whether the effect of glucose and AGEs on human peritoneal me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab998a37318338188b4d664ad9f82da0
https://doi.org/10.1038/sj.ki.5002016
https://doi.org/10.1038/sj.ki.5002016
Autor:
A. Yovine, F Turpin, M. Riofrio, Laurent Zelek, M. Spielmann, Etienne Brain, A. Taamma, Jose Jimeno, Jean-Louis Misset
Publikováno v:
British Journal of Cancer
Yondelis (trabectedin, ET-743) is a novel marine-derived anticancer compound found in the ascidian Ecteinascidia turbinata. It is currently under phase II/III development in breast cancer, hormone refractory prostate cancer, sarcomas and ovarian canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa68a3cf14e9d30aa2ad17aca131512b
https://doi.org/10.1038/sj.bjc.6603142
https://doi.org/10.1038/sj.bjc.6603142
Autor:
Werner Hilgers, Jean-Louis Misset, E. Cvitkovic, Jérôme Alexandre, Carmen Kahatt, G. Weems, Stéphanie Chieze, John R. MacDonald, Eric Raymond, François Lokiec, François Goldwasser, Sandrine Faivre, Abdelkrim Taamma
Publikováno v:
Investigational New Drugs. 24:311-319
Background: To determine maximum tolerated dose (MTD), recommended dose, safety and pharmacokinetics of irofulven combined with cisplatin in advanced solid tumor patients. Patients and methods: Cisplatin and irofulven were given sequentially i.v. ove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e890151d0328431059fdab1664069acf
https://doi.org/10.1007/s10637-005-5055-6
https://doi.org/10.1007/s10637-005-5055-6
Autor:
J.L. Misset, A. Taamma, Suzette Delaloge, Patricia Pautier, Nadia Chouaki, Esteban Cvitkovic, Catherine Lhommé, Abderahmane Laadem
Publikováno v:
American Journal of Clinical Oncology: Cancer Clinical Trials. 23:569-574
To determine the feasibility of the paclitaxel, oxaliplatin, cisplatin combination in advanced ovarian cancer (AOC), 15 patients with AOC (8 chemonaive, and 7 second-line, disease-free interval > or = 12 months) received paclitaxel 135 mg/m2 at day 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12e3b3b1b238b85338f5c9d856729faa
https://doi.org/10.1097/00000421-200012000-00007
https://doi.org/10.1097/00000421-200012000-00007
Autor:
Jonathan Simon, Esteban Cvitkovic, A. Taamma, Jean-Pierre Armand, A. Fandi, Mounir Bachouchi, Nacer Azli, François Eschwege, Hammouda Boussen, Pierre Wibault
Publikováno v:
Journal of Clinical Oncology. 18:1324-1330
PURPOSE: To review incidence and analyze profile of long-term complete responders among patients with undifferentiated carcinoma of nasopharyngeal type (UCNT) treated at a single institution. PATIENTS AND METHODS: We present a cohort of 20 long-term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e90fbe6121e8f348c387f3b06b2314
https://doi.org/10.1200/jco.2000.18.6.1324
https://doi.org/10.1200/jco.2000.18.6.1324